Potential drug-drug interactions in hospitalized pediatric patients with respiratory disorders: a retrospective review of clinically important interactions
- 31 January 2020
- journal article
- review article
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
Abstract
Background Hospitalized pediatric patients are at an increased risk of experiencing potential drug-drug interactions (pDDIs) due to polypharmacy and the unlicensed and off-label administration of drugs. The aim of this study is to characterize clinically significant pDDIs in pediatric patients hospitalized in a tertiary respiratory center. Methods A retrospective analysis of medications prescribed to pediatric patients admitted to the pediatric ward (PW) and pediatric intensive care unit (PICU) of a respiratory referral center was carried out over a six-month period. The pDDIs were identified using the Lexi-Interact database and considered as clinically relevant according to the severity rating as defined in the database. Frequency, drug classes, mechanisms, clinical managements, and risk factors were recorded for these potential interactions. Results Eight hundred and forty-five pDDIs were identified from the analysis of 176 prescriptions. Of the total pDDIs, 10.2% in PW and 14.6% in PICU were classified as clinically significant. Anti-infective agents and central nervous system drugs were the main drug classes involved in clinically significant pDDIs as object and/or precipitant drugs. A higher number of medications [odds ratio (OR): 4.8; 95% confidence interval (CI): 2.0–11.4; p < 0.001] and the existence of a nonrespiratory disease, which led to a respiratory disorder (OR: 3.8; 95% CI: 1.40–10.4; p < 0.05), were the main risk factors associated with an increased incidence of pDDIs. Conclusions A high and similar risk of pDDIs exists in pediatric patients with respiratory disorders hospitalized in PW and PICU. The patients prescribed a higher number of medications and presenting respiratory symptoms induced by a nonrespiratory disease require extra care and monitoring. Pediatricians should be educated about clinically significant DDIs for highly prescribed medications in their settings in order to take preventive measures and safeguard patient safety.Keywords
This publication has 24 references indexed in Scilit:
- Clinical Characteristics and Immunogenetics of BCGosis/BCGitis in Chinese Children: A 6 Year Follow-Up StudyPLOS ONE, 2014
- Core Drug-Drug Interaction Alerts for Inclusion in Pediatric Electronic Health Records With Computerized Prescriber Order EntryJournal of Patient Safety, 2014
- Potential drug–drug interactions in pediatric outpatient prescriptions for newborns and infantsComputer Methods and Programs in Biomedicine, 2014
- Age Related Changes in Fractional Elimination Pathways for Drugs: Assessing the Impact of Variable Ontogeny on Metabolic Drug-Drug InteractionsThe Journal of Clinical Pharmacology, 2013
- Do Children Have the Same Vulnerability to Metabolic Drug–Drug Interactions as Adults? A Critical Analysis of the LiteratureThe Journal of Clinical Pharmacology, 2013
- Incidence of potential drug interactions in medication prescriptions for children and adolescents in the University Hospital Olomouc, Czech RepublicEuropean Journal of Pediatrics, 2013
- Clinical Usefulness of Electronic Drug-Drug Interaction Checking in the Care of Cardiovascular Surgery InpatientsCardiology, 2012
- QT prolongation in the intensive care unit: commonly used medications and the impact of drug–drug interactionsExpert Opinion on Drug Safety, 2010
- Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literatureJournal of Clinical Pharmacy & Therapeutics, 2009
- How children's responses to drugs differ from adultsBritish Journal of Clinical Pharmacology, 2005